-
公开(公告)号：US20160015725A1
公开(公告)日：2016-01-21
申请号：US14378691
申请日：2013-02-14
发明人： Young Chan Chae , Dario C. Altieri
IPC分类号： A61K31/675 , A61K31/7004 , G01N33/574 , A61K31/19 , C12Q1/68 , A61K45/06 , A61K31/4706
CPC分类号： A61K31/675 , A61K31/19 , A61K31/4706 , A61K31/519 , A61K31/7004 , A61K45/06 , C12Q1/6886 , C12Q2600/158 , G01N33/57496 , G01N2333/4703 , A61K2300/00
摘要： Methods of stimulating anti-tumor activity in a subject with cancer are provided. The methods include administering to a subject in need thereof a low dose low dosage of a composition comprising a molecule that inhibits Hsp90 linked to a mitochondria-penetrating moiety; and administering to the subject an effective amount of an inhibitor of autophagy or glycolysis.
摘要翻译： 提供了刺激患有癌症的受试者的抗肿瘤活性的方法。 所述方法包括向有需要的受试者施用低剂量的包含抑制与线粒体穿透部分连接的Hsp90的分子的组合物; 并向受试者施用有效量的自噬或糖酵解抑制剂。
-
公开(公告)号：US20240342199A1
公开(公告)日：2024-10-17
申请号：US18609635
申请日：2024-03-19
IPC分类号： A61K31/665 , A61K31/4745 , A61K31/501 , A61K31/519 , A61K31/5377 , A61K31/585 , A61K31/66 , A61K45/06
CPC分类号： A61K31/665 , A61K31/4745 , A61K31/501 , A61K31/519 , A61K31/5377 , A61K31/585 , A61K31/66 , A61K45/06
摘要： Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment, the composition comprises Gamitrinib and a PI3K inhibitor selected from PX-866, AZD6482, LY294002, BEZ235, GSK458, GDC0941, ZSTK474, BKM120 and GSK2636771B. Methods of treating cancer are also provided.
-
公开(公告)号：US11208478B2
公开(公告)日：2021-12-28
申请号：US16323648
申请日：2017-08-04
发明人： Dario C. Altieri
IPC分类号： C07K16/28 , A61K31/167 , A61K31/444 , A61K31/496 , A61K31/519 , A61K31/5383 , G01N33/573 , G01N33/574 , A61K45/06 , A61K31/385 , A61K31/19 , A61K31/4439 , A61K31/20 , A61P35/00
摘要： Therapeutic treatments of a tumor expressing pT346 PDK1, including glioma expressing pT346 PDK1, are disclosed.
-
公开(公告)号：US20190255081A1
公开(公告)日：2019-08-22
申请号：US16254919
申请日：2019-01-23
IPC分类号： A61K31/665 , A61K31/66 , A61K31/519 , A61K31/585 , A61K45/06 , A61K31/501 , A61K31/4745 , A61K31/5377
摘要： Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment, the composition comprises Gamitrinib and a PI3K inhibitor selected from PX-866, AZD6482, LY294002, BEZ235, GSK458, GDC0941, ZSTK474, BKM120 and GSK2636771B. Methods of treating cancer are also provided.
-
公开(公告)号：US20170049790A1
公开(公告)日：2017-02-23
申请号：US15308130
申请日：2015-05-01
IPC分类号： A61K31/665 , A61K45/06 , A61K31/501 , A61K31/4745 , A61K31/5377 , A61K31/585
CPC分类号： A61K31/665 , A61K31/4745 , A61K31/501 , A61K31/519 , A61K31/5377 , A61K31/585 , A61K31/66 , A61K45/06 , A61K2300/00
摘要： Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises Gamitrinib and a P13K inhibitor selected from PX-866, AZD6482, LY294002. BEZ235, GSK458, GDCO941, ZSTK474, BKM120 and GSK2636771B. Methods of treating cancer are also provided. The present invention is based in part on the inventor's discovery that combination therapy that targets mitochondria eliminates tumor adaptation induced by P13K inhibition, and improves clinical outcome in cancer.
摘要翻译： 提供了用于治疗癌症的药物组合物。 在一个实施方案中，组合物包含Gamitrinib和选自PX-866，AZD6482，LY294002的P13K抑制剂。 BEZ235，GSK458，GDCO941，ZSTK474，BKM120，GSK2636771B。 还提供了治疗癌症的方法。 本发明部分基于发明人的发现，靶向线粒体的联合治疗消除了由P13K抑制引起的肿瘤适应性，并改善了癌症中的临床结果。
-
公开(公告)号：US20210186993A1
公开(公告)日：2021-06-24
申请号：US16987974
申请日：2020-08-07
IPC分类号： A61K31/665 , A61K45/06 , A61K31/519 , A61K31/66 , A61K31/4745 , A61K31/501 , A61K31/5377 , A61K31/585
摘要： Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment, the composition comprises Gamitrinib and a PI3K inhibitor selected from PX-866, AZD6482, LY294002, BEZ235, GSK458, GDC0941, ZSTK474, BKM120 and GSK2636771B. Methods of treating cancer are also provided.
-
公开(公告)号：US20210069218A1
公开(公告)日：2021-03-11
申请号：US16833144
申请日：2020-03-27
发明人： Young Chan Chae , Dario C. Altieri
IPC分类号： A61K31/675 , A61K45/06 , A61K31/4706 , A61K31/519 , A61K31/19 , A61K31/7004 , C12Q1/6886 , G01N33/574
摘要： Methods of stimulating anti-tumor activity in a subject with cancer are provided. The methods include administering to a subject in need thereof a low dose low dosage of a composition comprising a molecule that inhibits Hsp90 linked to a mitochondria-penetrating moiety; and administering to the subject an effective amount of an inhibitor of autophagy or glycolysis.
-
公开(公告)号：US20170000804A1
公开(公告)日：2017-01-05
申请号：US15192516
申请日：2016-06-24
IPC分类号： A61K31/585 , C12Q1/68 , A61K31/7088 , G01N33/50 , A61K31/395 , C12N15/113
CPC分类号： A61K31/585 , A61K31/366 , A61K31/395 , A61K31/5377 , A61K31/7088 , A61K45/06 , C12N15/1137 , C12N2310/14 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178 , C12Y207/01137 , G01N33/5011 , G01N33/5079 , A61K2300/00
摘要： Methods for reducing, inhibiting or preventing cancer metastasis comprise blocking the movement of mitochondria within a cancer cell. Other methods involve interrupting or preventing oxidative phosphorylation pathways or respiration pathways in the cancer cell. In one embodiment, mitochondrial movement is induced by contact of the cell with PI3K inhibitors or antagonists. Methods for treating cancer involve a regimen of treating a subject with a PI3K inhibitor or antagonist and treating the subject with a composition that blocks the movement of mitochondria within the subject's cells.
摘要翻译： 降低，抑制或预防癌症转移的方法包括阻断癌细胞内线粒体的运动。 其他方法涉及中断或预防癌细胞中的氧化磷酸化途径或呼吸途径。 在一个实施方案中，通过细胞与PI3K抑制剂或拮抗剂的接触诱导线粒体运动。 用于治疗癌症的方法涉及用PI3K抑制剂或拮抗剂治疗受试者的方案，并用阻断受试者细胞内线粒体运动的组合物治疗受试者。
-
公开(公告)号：US20140271667A1
公开(公告)日：2014-09-18
申请号：US14211394
申请日：2014-03-14
发明人： Dario C. Altieri , Young Chan Chae
IPC分类号： A61K45/06 , A61K31/395 , A61K39/395 , C07K16/40 , C07K16/18
CPC分类号： A61K45/06 , A61K31/66 , A61K39/39558 , A61K2300/00
摘要： A method for inhibiting tumor cell migration or metastasis of a cancer in a mammalian subject comprises one or more of the steps of administering to a subject a therapeutically effective amount of a composition comprising a molecule that: suppresses focal adhesion kinase (FAK) activity or phosphorylation; suppresses ULK1 kinase activity; suppresses activation or signaling of the mTORC1 (Ser757) pathway; activates AMPK; activates FIP200; or activates LKB1, in a cancer cell. Still another method of inhibiting tumor cell migration involves inhibiting phosphorylation of ULK1 on Ser757 in subjects with lung cancer. Suppressing activation or signaling of the mTORC1 (Ser757) pathway in subjects is in one aspect useful in treating lung cancer.
摘要翻译： 用于抑制哺乳动物受试者中肿瘤细胞迁移或转移的方法包括以下步骤：向受试者施用治疗有效量的包含分子的组合物：抑制粘着斑激酶（FAK）活性或磷酸化 ; 抑制ULK1激酶活性; 抑制mTORC1（Ser757）途径的激活或信号传导; 激活AMPK; 激活FIP200; 或激活LKB1，在癌细胞中。 抑制肿瘤细胞迁移的另一种方法是在肺癌患者的Ser757上抑制ULK1的磷酸化。 在受试者中抑制mTORC1（Ser757）途径的激活或信号传导在一个方面可用于治疗肺癌。
-
公开(公告)号：US20190177411A1
公开(公告)日：2019-06-13
申请号：US16323648
申请日：2017-08-04
发明人： Dario C. Altieri
IPC分类号： C07K16/28 , A61P35/00 , A61K31/167 , A61K31/5383 , A61K31/444 , A61K31/496 , A61K31/519 , G01N33/574 , G01N33/573
摘要： Therapeutic treatments of a tumor expressing pT346 PDK1, including glioma expressing pT346 PDK1, are disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.025 秒)
